PROJECTS
>>Ramp up of Product Development Efficiencies
>>Transformation through In-Licensing & Site Transfers
>>Out-License of New Molecular Entity by Biotech Footprint Late
>>Strengthening of Overseas Footprint
>>Divestment of Late Life Cycle Products
>>Commercializing a Reformulated Product
>>Business Development for Development Stage Enabling Technology
>>Restructuring Clinical Operations
>>Optimal Drug Development Path and Licensing Process
>>Post-Merger integration of Research and Development operations
Optimal Drug Development Path and Licensing Process
Garphi was retained by a specialty pharmaceutical company seeking to determine the optimal development path and appropriate licensing terms for a development-stage molecule with potential in multiple indications and therapeutic areas. Garphi through another of its associates leveraged their proprietary R&D benchmarking methodology to collect and analyze historical drug development data for over 1900 clinical programs of interest from 1994-2008. R&D benchmarking data were combined with licensing and market metrics to prioritize 23 high-interest indications, according to their strategic and clinical attractiveness in the context of the company’s overall strategy.
• R&D metrics included: Probability of successful Phase II to Phase III transition, time in phase and historical licensing activity for each indication
• Additional metrics for target markets included (among several others): size, competitive environment, un-met need, complexity of clinical trials and reimbursement landscape
Garphi also reviewed relevant comparable deals to determine the appropriate license structure and terms and to develop a framework for valuation. After an in-depth analysis Garphi and its associate recommended the optimal license structure for use in deal negotiations.
